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ABSTRACT: As a driver for many biological processes, phosphor-
ylation remains an area of intense research interest. Advances in
multiplexed quantitation utilizing isobaric tags (e.g., TMT and
iTRAQ) have the potential to create a new paradigm in quantitative
proteomics. New instrumentation and software are propelling these
multiplexed workﬂows forward, which results in more accurate,
sensitive, and reproducible quantitation across tens of thousands of
phosphopeptides. This study assesses the performance of multi-
plexed quantitative phosphoproteomics on the Orbitrap Fusion mass
spectrometer. Utilizing a two-phosphoproteome model of precursor
ion interference, we assessed the accuracy of phosphopeptide
quantitation across a variety of experimental approaches. These
methods included the use of synchronous precursor selection (SPS)
to enhance TMT reporter ion intensity and accuracy. We found that (i) ratio distortion remained a problem for phosphopeptide
analysis in multiplexed quantitative workﬂows, (ii) ratio distortion can be overcome by the use of an SPS-MS3 scan, (iii)
interfering ions generally possessed a diﬀerent charge state than the target precursor, and (iv) selecting only the phosphate
neutral loss peak (single notch) for the MS3 scan still provided accurate ratio measurements. Remarkably, these data suggest that
the underlying cause of interference may not be due to coeluting and cofragmented peptides but instead from consistent, low
level background fragmentation. Finally, as a proof-of-concept 10-plex experiment, we compared phosphopeptide levels from ﬁve
murine brains to ﬁve livers. In total, the SPS-MS3 method quantiﬁed 38 247 phosphopeptides, corresponding to 11 000
phosphorylation sites. With 10 measurements recorded for each phosphopeptide, this equates to more than 628 000 binary
comparisons collected in less than 48 h.
As a key mediator of cellular signaling, phosphorylationremains a principal target for biological interrogation.1
Identifying and quantifying the phosphorylation state of
proteins involved in cell progression, metabolism, growth,
and disease is critical for the continued elucidation of cellular
function.2 Global phosphoproteome characterization is chal-
lenging due to the estimated large volume of phosphorylation
sites in eukaryotic cells and the often low abundance/
stoichiometry of the phosphoproteome.3,4 Continuing techno-
logical and methodological advancements have resulted in the
characterization of tens of thousands of phosphorylation sites
across numerous species, but it is apparent that only a fraction
of all phosphorylation events have been characterized.5−11
Furthermore, phosphorylation dynamics, assessed via relative
quantiﬁcation, have historically been limited to binary or
ternary comparisons, further limiting the breadth and depth of
phosphopeptide analysis.12−17 Novel methodologies are needed
in order to overcome the current shortcomings of phospho-
proteome characterization.
Mass spectrometry remains an unmatched platform for
comprehensive phosphoproteome analysis. Coupling deep
identiﬁcation with relative quantiﬁcation has provided valuable
biological insights that would be otherwise unobtainable by
traditional biochemical techniques.18−24 Isobaric tags for
relative and absolute quantitation (iTRAQ) and tandem-
mass-tag (TMT) based methodologies permit the simultaneous
comparison of up to 8 (iTRAQ) or 10 (TMT) samples,
facilitating complex experimental designs and the inclusion of
biological replicates within the same experiment.
A primary hurdle for isobaric based quantiﬁcation
technologies is the presence of interfering coisolated species
that result in distorted reporter ion intensities. A number of
publications have documented this phenomenon, and several
have demonstrated approaches to alleviate the interfer-
ence.25−31 One such approach was the inclusion of a
quantitative MS3 spectrum.32
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Recently, the sensitivity of the MS3 method was dramatically
improved by isolating multiple fragment ions in the MS2
spectrum using isolation waveforms with multiple notches (e.g.,
synchronous precursor selection, SPS).33 The SPS-MS3
method is available on the Orbitrap Fusion, which leverages
advancements in software and hardware to provide increased
scan rates and improved sensitivity, resolution, and quantitative
accuracy. Furthermore, a unique architecture expands the
concept of a hybrid mass spectrometer by incorporating three
mass analyzers (i.e., quadrupole mass ﬁlter, quadrupole ion
trap, and Orbitrap) operating in a task parallelized manner.
Here, we assessed the performance of the SPS-MS3 method
on two diﬀerent phosphoproteome samples. We utilized a 2-
phosphoproteome model of interference to characterize the
quantitative accuracy of various SPS-MS3 and MS2 methods on
the Orbitrap Fusion. We observed that known ratios were
distorted for the MS2 method compared to the SPS-MS3
method. In a large-scale demonstration of the method, we
performed a proteome-wide phosphorylation analysis in 48 h,
which compared brain and liver phosphorylation level diﬀer-
ences from ﬁve mice in a single 10-plex experiment.
■ EXPERIMENTAL PROCEDURES
Protein Extraction and Digestion. Five murine brains
and livers were harvested from CO2 asphyxiated 3-week-old
male Swiss-Webster mice (Jackson Lab, Bar Harbor, ME).
Saccharomyces cerevisiae cells were grown to an OD of 1.0,
washed with ice cold PBS and snap frozen in liquid N2 until
further use. Brain/liver tissues and yeast cells were mechanically
lysed with a homogenizer in SDS lysis buﬀer [2.0% SDS w/v,
250 mM NaCl, PhosSTOP (Roche, Madison, WI) phosphatase
inhibitors, 2 mM sodium vanadate, EDTA free protease
inhibitor cocktail (Promega, Madison, WI), and 50 mM
HEPES, pH 8.5]. Lysates were reduced with 5 mM DTT and
cysteine residues alkylated with iodoacetamide (14 mM) in the
dark (30 min). Protein was extracted by methanol−chloroform
precipitation and subsequent ice cold acetone washes. Pellets
were dried and resuspended in 8 M urea containing 50 mM
HEPES (pH 8.5). Protein concentrations were measured by
BCA assay (Thermo Scientiﬁc, Rockford, IL) prior to protease
digestion. Protein lysates were diluted to 4 M urea and digested
with LysC (Wako, Japan) in a 1/200 enzyme/protein ratio
overnight. Protein extracts were diluted further to a 1.5 M urea
concentration, and trypsin (Promega, Madison, WI) was added
to a ﬁnal 1/250 enzyme/protein ratio for 6 h at 37 °C. Digests
were acidiﬁed with 200 μL of 20% formic acid (FA) to a pH ∼2
and subjected to C18 solid-phase extraction (SPE) (Sep-Pak,
Waters, Milford, MA).
Phosphopeptide Enrichment. As the proportion of
phosphopeptides identiﬁed from nonphosphopeptide enriched
proteomes is routinely <5%, a suﬃcient amount of starting
material is necessary in order to produce a phosphopeptide
population amenable to LC−MS. Given the amount of starting
material, it is prudent to consider the costs of TMT reagents.
The methods have been optimized to incorporate TMT
labeling post phosphopeptide enrichment, resulting in a
signiﬁcant cost reduction. For example, TMT labeling post
phosphopeptide enrichment results in at least a 40-fold
reduction in peptide concentration, providing a corresponding
savings in TMT reagent cost.
Enrichment proceeded with some modiﬁcations to the
method of Kettenbach et al.34 Tryptic peptides (∼10 mg per
TMT channel) were resuspended in 1 mL of 2 M lactic acid/
50% acetonitrile (ACN) and centrifuged at 15 000g for 20 min.
Supernatants were removed, placed in an Eppendorf tube
containing 15 mg of titanium dioxide beads (GL Sciences,
Figure 1. (A) Murine brain and yeast lysates were digested and phosphopeptides enriched by TiO2. The mouse phosphopeptides were labeled with
TMT and mixed at a relative concentration of 10:2:1:1:2:10. Yeast phosphopeptides were split into three samples, labeled with three TMT reagents,
and mixed 10:10:10:0:0:0. The mouse and yeast phosphopeptides were mixed (1:1, w:w). If present, interference from the yeast background would
perturb mouse ratios. For all mouse phosphopeptides, the TMT channels lacking any yeast interference provided control intensities and ratios. (B)
SPS-MS3 method overview. Synchronous precursor selection (SPS) enables the simultaneous isolation of multiple MS2 fragment ions increasing
TMT reporter ion signal in the MS3 scan.
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Japan), and vortexed for 1 h at room temperature. Beads were
washed twice with 2 M lactic acid/50% ACN and once with
0.1% TFA in 50% ACN. Phosphopeptides were eluted twice
with 150 μL of 50 mM HK2PO4, pH 10, acidiﬁed with 40 μL of
20% formic acid, and subjected to C18 StageTip desalting (3M
Empore, South Eagan, MN).
Tandem Mass Tagging Labeling. Isobaric labeling of the
enriched phosphopeptides was performed using either the 6-
plex or 10-plex tandem mass tag (TMT) reagents (Thermo
Fisher Scientiﬁc, Rockford, IL). TMT reagents (0.8 mg) were
dissolved in 40 μL of dry acetonitrile (ACN), and 10 μL was
added to 100 μg (Micro BCA, Thermo Scientiﬁc, Rockford, IL)
of phosphopeptides dissolved in 100 μL of 200 mM HEPES,
pH 8.5. After 1 h (RT), the reaction was quenched by adding 8
μL of 5% hydroxylamine. Labeled peptides were combined,
acidiﬁed with 20 μL of 20% FA (pH ∼2), and concentrated via
C18 SPE on Sep-Pak cartridges (50 mg bed volume). All
previously described sample preparation proceeded the same
for both the 6-plex and the 10-plex experiments. Additional
details regarding the 6-plex sample preparation is highlighted
below.
Two-Proteome Interference Model. Following phospho-
peptide labeling, the brain and yeast samples were combined.
Brain phosphopeptides were mixed together at 10:2:1:1:2:10
(TMT channels 126−131), and yeast phosphopeptides were
mixed at 10:10:10:0:0:0 (TMT channels 126−128) (Figure
1A). After combining the phosphopeptides, samples were
subjected to C18 solid-phase extraction (50 mg vide supra).
Basic pH Reverse-Phase HPLC (bpHrp). TMT labeled
brain and liver phosphopeptides were subjected to orthogonal
basic-pH reverse phase (bpHrp) fractionation. Labeled
phosphopeptides were solubilized in buﬀer A (5% ACN, 10
mM ammonium bicarbonate, pH 8.0) and separated on an
Agilent 300 Extend C18 column (5 μm particles, 4.6 mm i.d.
and 220 mm in length). Using an Agilent 1100 binary pump
equipped with a degasser and a photodiode array (PDA)
detector (Thermo Scientiﬁc, San Jose, CA), a 45 min linear
gradient from 8% to 35% acetonitrile in 10 mM ammonium
bicarbonate pH 8 (ﬂow rate of 0.8 mL/min) separated the
peptide mixtures into a total of 96 fractions. The 96 fractions
were consolidated into 24 samples in a checkerboard manner,
acidiﬁed with 10 μL of 20% formic acid and vacuum-dried.
Each sample was redissolved in 5% formic acid, desalted via
StageTip, dried via vacuum centrifugation, and reconstituted for
LC−MS/MS analysis.
Orbitrap Fusion Parameters. All spectra were acquired on
an Oribtrap Fusion (Thermo Fischer Scientiﬁc) coupled to an
Easy-nLC 1000 (Thermo Fisher Scientiﬁc) ultrahigh pressure
liquid chromatography (UHPLC) pump. Peptides were
separated on an in-house packed 100 μM inner diameter
column containing 0.5 cm of Magic C4 resin (5 μm, 100 Å,
Michrom Bioresources), serving as a frit, followed by 25 cm of
Sepax Technologies GP-C18 resin (1.8 μm, 120 Å, Newark,
DE) with a gradient consisting of 3−22% (ACN, 0.125% FA)
over 165 min at ∼300 nL/min.
For all experiments, the instrument was operated in the data-
dependent mode. We collected FTMS1 spectra at a resolution
of 120 000, with an automated gain control (AGC) target of
200 000, and a max injection time of 100 ms. The 10 most
intense ions were selected for MS/MS. Precursors were ﬁltered
according to charge state (required >1 z), and monoisotopic
peak assignment. Previously interrogated precursors were
excluded using a dynamic window (75 s ± 10 ppm). The
MS2 precursors were isolated with a quadrupole mass ﬁlter set
to a width of 0.5 m/z.
During the experiment where precursors were only analyzed
by FTMS2, the Orbitrap was operated at 60 000 resolution,
with an AGC target of 50 000 and a max injection time of 250
ms. Precursors were fragmented by high-energy collision
dissociation (HCD) at a normalized collision energy (NCE)
of 37.5%.
During the method with FTMS3 analysis, ITMS2 spectra
were collected at an AGC of 4 000, max injection time of 150
ms, and CID collision energy of 35%. FTMS3 spectra utilized
the same Orbitrap parameters as the FTMS2 method, except
HCD collision energy was increased to 55% to ensure maximal
TMT reporter ion yield. Depending on the experiment,
synchronous-precursor-selection (SPS) was enabled to include
up to 3, 6, or 10 MS2 fragment ions in the FTMS3 scan.
Data Processing and Spectra Assignment. A compila-
tion of in-house software was used to convert mass
spectrometric data (Thermo “.raw” ﬁles) to mzXML format
as well as to correct monoisotopic m/z measurements and
erroneous peptide charge state assignments. Assignment of
MS/MS spectra was performed using the SEQUEST
algorithm.35 The 2-phosphoproteome experiment utilized a
protein sequence database that was a combination of the
Mouse UniProt database (downloaded 08/02/2011) and the S.
cerevisiae ORF database (downloaded 02/16/2010). All other
experiments utilized only the Mouse UniProt database. In each
case, reversed protein sequences were appended as well as
known contaminants such as human keratins. In order to
prevent inaccurate interference measurements from peptides
shared by yeast and mouse, the 2-phosphoproteome FASTA
database was ordered such that protein sequences from yeast
were listed ﬁrst, thus ensuring that peptides matching both
yeast and mouse proteins would be assigned to a yeast protein.
SEQUEST searches were performed using a 50 ppm precursor
ion tolerance, while requiring each peptide’s N/C terminus to
have trypsin protease speciﬁcity and allowing up to two missed
cleavages. TMT tags on peptide N termini/lysine residues
(+229.162932 Da) and carbamidomethylation of cysteine
residues (+57.02146 Da) were set as static modiﬁcations,
while methionine oxidation (+15.99492 Da) and serine,
threonine, and tyrosine phosphorylation (+79.96633 Da)
were set as variable modiﬁcations. An MS2 spectra assignment
false discovery rate (FDR) of less than 1% was achieved by
applying the target-decoy database search strategy.36 Filtering
was performed exactly as previously described.33
We used a modiﬁed version of the Ascore algorithm to
quantify the conﬁdence with which each phosphorylation site
could be assigned to a particular residue. Phosphorylation sites
with Ascore values >13 (P ≤ 0.05) were considered conﬁdently
localized to a particular residue.11
Determination of TMT Reporter Ion Intensities and
Quantitative Data Analysis. For quantiﬁcation, a 0.03 m/z
(6-plex TMT) or 0.003 m/z (10-plex TMT) window centered
on the theoretical m/z value of each reporter ion was queried
for the nearest signal intensity. Reporter ion intensities were
adjusted to correct for the isotopic impurities of the diﬀerent
TMT reagents (manufacturer speciﬁcations). The signal-to-
noise values for all peptides were summed within each TMT
channel, and each channel was scaled according to the
interchannel diﬀerence of these sums to account for diﬀerences
in sample handling. For each peptide, a total minimum sum
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signal-to-noise value of 400 and an isolation purity greater than
75% was required.33
Neutral loss fragments were identiﬁed by parsing MS2
spectra for fragments within 0.2 m/z of the expected mass
(based on precursor m/z and charge state) and with an
intensity greater than 10% of the base peak intensity.
t tests with Welch’s correction for unequal variances were
performed for all mouse brain and liver phosphopeptide
biological replicates. Multiple test correction was performed by
adjusting the calculated p-values according to Benjamini−
Hochberg.37 Phosphopeptides with an adjusted p-value < 0.01
were classiﬁed as brain enriched, liver enriched, or commonly
expressed. Gene ontology term enrichment was performed by
submitting the three classes described above to DAVID,
utilizing the complete set of quantiﬁed phosphopeptides as a
background.38 All data analysis was performed using R (R Core
Team, Vienna, Austria, http://www.R-project.org).
■ RESULTS
Constructing a 2-Phosphoproteome Model of Inter-
ference. To assess the accuracy of TMT-based quantitative
phosphoproteomics on the Orbitrap Fusion, we constructed a
2-phosphoproteome sample that contains TMT channels with
and without interfering phosphopeptides. Figure 1A illustrates
the preparation of the 2-phosphoproteome model. Following
tissue lysis, digestion, and phosphopeptide enrichment, the
mouse brain phosphopeptides were combined at a concen-
tration of 10:2:1:1:2:10. To introduce interference, yeast
phosphopeptides were mixed at a concentration of
10:10:10:0:0:0 and added to the mouse phosphopeptide
dilution series (1:1 w/w). The resulting sample of mouse
phosphopeptides contained three channels that might display
interference from coisolated yeast phosphopeptides (m/z 126,
127, and 128) and three channels that were free of any yeast
interference (m/z 129, 130, and 131). If present, interference
would distort the expected ratios between channels 126 and
127 (5:1) and 126 and 128 (10:1). The SPS-MS3 method
implemented here incorporated a notched isolation waveform
(up to 10 notches) that isolated MS2 fragment ions based upon
their relative intensity (Figure 1B).
Assessing Quantitative Phosphoproteome Accuracy.
We used the 2-phosphoproteome model to assess the
quantitative accuracy of several MS methods for phosphor-
ylation analysis. Figure 2 shows the normalized TMT ratios for
the 5:1 comparison with and without interference (red trace
126/127, blue trace 131/130, respectively). Yeast peptides are
plotted in green and were expected to have a 1:1 ratio.
As has been observed in previous studies,29−32 TMT reporter
ion intensities derived from MS2 spectra were largely distorted
and inaccurate (Figure 2A). We observed that a narrow
quadrupole mass ﬁlter isolation of 0.5 m/z did not eﬀectively
correct interference. Furthermore, the ratio between yeast
phosphopeptides, which represented the most intense and
easiest measurement at 1:1, was also distorted, by the mouse
phosphopeptides, to a median of 1.2:1.
For each SPS method, the distribution of ratios for the
interference channel followed that of the MS3 single notch
method (Figure 2B). Distributions were tight and centered
about the expected ratio of 5:1. However, as more of the MS2
spectral space was included in the MS3 scan, we observed a
subtle shift in the distributions of ratios (Figure 2C−E). This is
apparent as the diﬀerence between the noninterference
distribution (blue) and the interference distribution (red)
Figure 2. Phosphopeptide mixture was analyzed by LC−MS and
quantiﬁed by MS2 and SPS-MS3 methods. SPS-MS3 performance was
further investigated by varying the number of MS2 fragment ions
included in the quantitative MS3 spectrum (i.e., 1, 3, 6, and 10
precursor ions). (A−E) Distributions of ratios corresponding to yeast
phosphopeptides (TMT channels 126/127, green trace), mouse
phosphopeptides with interference (TMT channels 126/127, red
trace), and mouse phosphopeptides without interference (TMT
channels 131/130, blue trace). Yeast phosphopeptides (green) are
expected at a 1:1 ratio while the mouse phosphopeptides were mixed
at a 5:1 ratio (red and blue). The dashed line depicts the expected
ratio of 5:1. The number of quantiﬁed mouse phosphopeptides is
displayed for each method. Quantiﬁcation via an MS2 method (A)
resulted in signiﬁcant ratio distortion with a wide distribution of ratios.
Utilizing a MS3 method (B−E) dramatically improves the accuracy
and precision (fwhm) of phosphopeptide quantiﬁcation.
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increased as the number of notches increased. The correlation
between the increase in TMT reporter ion distortion and the
number of notches is likely a phenomenon speciﬁc to
phosphopeptide analyses (see below).
Neutral Loss and TMT Accuracy. A common character-
istic of phosphopeptide analysis is the presence of a dominant
neutral loss peak following CID fragmentation. We examined
the 2-phosphoproteome data set to assess the impact, if any, a
dominant phosphate neutral loss fragment plays in quantitative
accuracy. Identiﬁcation of typical phosphate neutral loss
fragments was accomplished by searching MS2 spectra for
fragment ions corresponding to the expected neutral loss
masses based on precursor charge state and m/z (see
Experimental Procedures).
Figure 3A depicts the proportion of mouse phosphopeptides
with and without a neutral loss fragment (neutral loss greater
than 10% of base peak intensity). An overwhelming 82% of
phosphopeptides exhibited a neutral loss fragment following
CID fragmentation. Among those phosphopeptides that
produced a neutral loss, 70% of the neutral loss fragments
were identiﬁed as the most intense fragment in the MS2
spectrum, which translates to 57% of all phosphopeptides.
Across phosphopeptide charge states 2−5, neutral loss
fragments are consistently observed; although, as previously
reported the intensity of the neutral loss decreases as charge
state increases (Figure 3A, inset).39
For the SPS methods, we observed an increase in the degree
of TMT reporter inaccuracy as the number of MS2 fragment
ions included in the MS3 analysis was increased. The SPS-MS3
approach utilizes an intensity based rank order when selecting
MS2 fragments ions. That is, for a single notch MS3 method,
the most intense ion will be isolated for subsequent MS3; for a
three notch SPS method, the three most intense fragment ions
will be selected and so on. We believe that the increase in
interference may be due to the neutral loss retaining the bulk of
the precursor ion population, as observed by the rank order
intensity of the neutral loss. The inclusion of additional MS2
fragment ions via the SPS-MS3 method results in an increase in
the amount of MS2 m/z space included in the MS3 spectrum
without a corresponding increase in the target precursor ion
population. This contrasts directly with nonphosphorylated
peptides, which exhibit heterogeneous fragmentation, where
additional notches in the SPS-MS3 method will likely
correspond to additional fragment ions from the intended
precursor. For nonphosphorylated peptides this ultimately
provides a proportionate increase of m/z space and target
precursor ion current (Supp. Figure 1 in the Supporting
Information). Therefore, a future iteration of the SPS-MS3
method could include an online, dynamic adjustment of the
number of notches in order to account for the heterogeneity of
the MS2 fragment ion population.
In order to isolate the eﬀect, if any, of the neutral loss
fragment on quantitative accuracy, we only looked at the
quantitative accuracy of the population of phosphopeptides
where the most intense fragment ion corresponded to the
neutral loss of the phosphate group. Figure 3B displays a
summary of TMT reporter ion intensities for this select group
of phosphopeptides from the single notch MS3 experiment.
The noninterference channels (blue bars) produced ratios of
9.9:1 (10:1 expected) and 4.8:1 (5:1 expected). The
interference channels (red bars) produced remarkably similar
ratios of 9.7:1 and 5.1:1 (10:1 and 5:1 expected, respectively).
This suggests that the inclusion of a neutral loss fragment
within the MS3 method does not signiﬁcantly aﬀect the
accuracy of the TMT quantitation. Furthermore, this supports
the notion that reporter ion interference may be caused by
species that are not the same charge state and mass as the target
precursor.30,31
Large-Scale Comparison of Mouse Brain and Liver
Phosphorylation Levels. In order to more fully assess the
performance of the Orbitrap Fusion, when applied to a TMT-
based quantitative phosphoproteomics experiment, we con-
structed a 10-plex sample comprised of the brains and livers of
ﬁve mice (Figure 4A). In addition to assessing the depth of the
Figure 3. (A) Production of a neutral loss fragment from the single notch MS3 experiment was assessed and determined that 82% of mouse
phosphopeptides yielded a neutral loss of phosphoric acid. In total, 50% of the neutral loss fragments were the most intense ion in the spectrum.
(Inset) A neutral loss fragment was routinely present among charge states two and three. The intensity of the neutral loss fragment decreased as the
charge state increased. (B) Phosphopeptides containing a rank one neutral loss, from the single notch MS3 method, were selected, and the mean
relative TMT abundances were determined for each channel (error bars ± 1 SD). Channels containing interference (m/z 126/127/128) and without
interference (m/z 129/130/131) are shown. Ratios between channels with and without interference were near expected values (10:1, 5:1), which
indicated that the neutral loss fragment ion was a viable MS3 precursor ion that maintains the quantitative accuracy of the method.
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phosphoproteome characterization, the replicate tissue meas-
urements also provided a means of assessing the overall utility
of the entire quantitative phosphoproteomics workﬂow.
Figure 4B depicts the scan sequence by which each
phosphopeptide precursor is interrogated. First the precursor
ion is interrogated using an ion trap MS2 scan (ITMS2). The
precursor ions are isolated with the quadrupole mass ﬁlter and
then fragmented by CID. Online, up to 10 fragment ions
(prioritized by intensity) are noted in the MS2 spectrum for
interrogation by SPS-MS3 in the subsequent scan. Following a
reinjection, isolation, and fragmentation of the MS1 precursor
ion, the previously determined MS2 ions are isolated via a
notched isolation waveform. This collection of fragment ions is
then further fragmented via HCD and passed to the Orbitrap
(SPS-MS3 or FTMS3). Quantitation occurs by measuring the
signal-to-noise (as a proxy for the number of ions) for each of
the TMT reporters.40
In total, we quantiﬁed more than 38 000 phosphopeptides in
this analysis. Because of ﬁltering for minimum TMT signal (see
Experimental Procedures), the identiﬁcation rate was higher
such that ∼80% of all the identiﬁed unique phosphopeptides
passed all thresholds. This resulted in 11 015 phosphorylation
sites and 2 958 composite phosphorylation sites quantiﬁed,
providing 13 973 total quantiﬁed phosphorylation forms
(Supplementary Table 1 in the Supporting Information).
In addition to assessing the depth of the phosphoproteome
coverage, we assessed the level of quantitative reproducibility
among biological replicates. An example of the intratissue
reproducibility is highlighted in Figure 5A. For each tissue, the
ratio of one biological replicate to all other biological replicates
Figure 4. (A) 10-plex TMT phosphopeptide preparation. Following proteolytic digestion, phosphopeptides were enriched by TiO2 and labeled with
the 10-plex TMT reagents. Subsequent oﬄine, basic pH reversed-phase fractionation was employed. (B) The instrument interrogated each sample
using a data-dependent, SPS-MS3 method. Following ITMS2 analysis of the precursor ions, up to 10 MS2 fragments (light gray bars) were isolated
and further fragmented to provide the quantitative MS3 spectrum. Reporter ion intensities corresponding to the 10 TMT channels were normalized,
scaled, and summarized for the ﬁve brain and liver replicates.
Figure 5. (A) Biological replicates were assessed for reproducibility. One biological replicate from brain (red) and liver (blue) was compared to all
other biological replicates. The tight distributions of ratios centered about 0 (log 2) indicated good reproducibility. In contrast, ratios of brain to liver
(black) display a wide distribution, highlighting the phosphoproteome diversity between the tissues. (B) Reproducible and accurate measurements
across all 10 samples permitted the stringent ﬁltering of tissue-enriched phosphopeptides. Liver (blue) and brain (red) enriched phosphopeptides
were identiﬁed through a Welch’s corrected t test. Vertical lines (blue and red) represent a 1.5-fold change in expression. In all, 83% of
phosphopeptides were signiﬁcantly enriched in the liver or brain (adjusted p-value < 0.01).
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Figure 6. (A) Relative abundances of 38 247 phosphopeptides from quintuplicate biological replicates of mouse livers and brains were plotted.
Statistical comparison (t test, adjusted p-values < 0.01) provided three clusters representing phosphopeptides enriched in the brain, the liver, or those
that were commonly expressed in both tissues. (B) GO term enrichment was performed on each cluster resulting in descriptive terms consistent with
the originating tissue. The dashed line represents the term frequency across all phosphopeptides. (C,D) Tissue speciﬁc pathways highlight the
phosphopeptide coverage and quantitative reproducibility of the sample preparation and method.
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was plotted, yielding a narrow distribution of ratios with an
apex centered at a ratio of one. To further highlight global
reproducibility, median correlation coeﬃcients (Pearson) for
both the brain and liver replicates were determined to exceed
0.85. Finally, replicate biological comparisons displayed
remarkable consistency with strong linear relationships (brain
mean r2 = 0.92, liver mean r2 = 0.88) (Supplementary Figure 2
in the Supporting Information).
Obtaining accurate measurements across all 10 tissues
provided the opportunity to stringently assess the phospho-
proteome diﬀerences between the brain and liver. Following a
Welch’s corrected t test for unequal variances and Benjamini−
Hochberg p-value correction for multiple testing, we observed
that 83% of phosphopeptides were signiﬁcantly enriched in
either the brain or liver (adjusted p-value < 0.01, Figure 5B).
The median fold change for brain-enriched peptides was 8-fold,
while liver-enriched peptides was 5-fold.
Scaled abundances for all quantiﬁed phosphopeptides were
compared among brain and liver replicates and plotted in
Figure 6A. Nearly half (45%) of phosphopeptides exhibited
signiﬁcant expression in the brain, 38% exhibited signiﬁcant
expression in the liver, and 17% had consistent expression
across both tissues. Gene ontology (GO) term enrichment was
employed to highlight the ﬁdelity of the measurements, and
signiﬁcantly enriched terms are highlighted in Figure 6B. Brain
enriched terms included Synapse (cellular component) and ion
channel activity (molecular function), while the liver speciﬁc
phosphopeptides matched to GO terms: Transition metal ion
binding (molecular function) and carboxylic acid catabolic
process (biological process). GO terms corresponding to the
subset of commonly expressed phosphopeptides included actin
(cellular component) and DNA binding (molecular function).
With this level of phosphoproteome coverage, it was possible
to highlight pathways corresponding to phosphopeptides
enriched in either the brain or liver (Figure 6C,D). For each
phosphopeptide, the relative abundance in the brain or liver
replicates is plotted. Figure 6C illustrates a calcium signaling
pathway that was observed to be highly brain speciﬁc. As
displayed, Grm5, a G-protein coupled glutamate receptor
initiates a signaling cascade through Gnaq, a signaling
transducer, and production of inositol 1,4,5-trisphosphate
(IP3) via Plcb1 and Plcd1. Stimulation of Itpr1 results in
calcium release from the endoplasmic reticulum and activation
of Calm1, ultimately resulting in the control of a number of
biological processes including long-term depression/potentia-
tion, MAPK signaling, and apoptosis. A liver speciﬁc pathway,
PPARα signaling, is displayed in Figure 6D. Long chain fatty
acids are transported via Slc27a2 and Fabp1. The RXR/PPARα
heterodimer is activated by 9-cis retinoic acid, and the presence
of fatty acids results in transcriptional activation of a number of
downstream targets, including those involved in fatty acid
transport (ACSL1 and Dbi) and cholesterol metabolism
(Cyp8b1 and Nr1h3). For all peptides, the site of phosphor-
ylation was localized via the Ascore algorithm.
■ DISCUSSION
Phosphorylation analysis diﬀers from proteome analysis in at
least two ways. First, phosphopeptide enrichment creates a
sample of dramatically reduced complexity (and potential
interference) since most peptides do not contain a phosphate
molecule. Nevertheless, we detected signiﬁcant distortion using
the 2-proteome model where both proteomes were made up of
phosphopeptides, demonstrating that interference remains a
problem for phosphorylation analysis. The starting amounts for
phosphorylation analysis are up to 100 times greater than for
proteome analysis. Thus, the phospho-enriched mixture from
10 mg of starting material may actually be of similar complexity
to the 100 μg of proteome material.
Second, MS/MS spectra derived from phosphopeptides are
commonly dominated by an intense fragment ion correspond-
ing to the neutral loss (NL) of phosphoric acid. Prior to this
work, there was some concern that the NL peak might
correspond with a signiﬁcant population of interfering ions.
However, excluding these peaks was not an option because it
would limit the resulting TMT-MS3 reporter ion population
too much. We found that ratio accuracy was only minimally
aﬀected by including the NL peak. Indeed, using a single MS3
notch, which selected the NL peak as the only source for MS3
ions, did not result in signiﬁcant ratio distortion. These results
strongly suggest that ratio distortion is caused by species that
are coisolated at the MS1 level and that diﬀer in charge state
from the target ion. This ﬁnding is in agreement with the
previous work by Coon and colleagues that demonstrated that
an alternative TMT puriﬁcation technique based on a proton
transfer reaction (PTR) also improves quantitative accu-
racy.30,31 On the basis of these results, we no longer believe
that ratio distortion is caused by coeluting peptides, which are
coisolated and cofragmented. Rather, we suspect that the
majority of interference is likely caused by sustained, low levels
of singly charged fragment ions created through the electro-
spray process (e.g., in source dissociation), which are in-turn
coisolated and cofragmented with the target precursor peptide.
Multiplexing experiments with isobaric tags have the
advantage that within one experiment there are no missing
values. This is in contrast to binary comparisons where multiple
experiments are required to compare all samples. For example,
we quantiﬁed more than 38 000 phosphopeptides. Each
phosphopeptide quantiﬁed produced 10 measurements from
the 10 reporter ions, greatly facilitating the statistical analyses.
Phosphorylation diﬀerences between brain and liver tissue were
very reproducible across biological replicates. Given that the
phosphopeptide enrichment step was performed prior to TMT
labeling and mixing, the enrichment step was also reproducible.
This is important because the alternative would be to label 1
mg or more of peptides with each reagent and then to combine
them prior to enrichment, which would have dramatically
increased the cost of the experiment.
We found that most phosphopeptides were present at
diﬀering levels depending on their tissue source. Only 17% of
phosphorylation sites were not assigned as signiﬁcantly
enriched in either the brain or the liver. Sites assigned to the
liver or brain were signiﬁcantly enriched for gene ontology
categories representative of the tissue of origin. For example,
categories such as “synapse” and “ion channel activity” were
frequently identiﬁed in brain and they are representative of the
underlying diﬀerence in signaling.
■ CONCLUSION
Quantitative multiplexed phosphoproteome characterization,
utilizing TMT reagents, presents an opportunity for unbiased
biological discovery. The ability to multiplex up to 10 replicates
or conditions in a single sample signiﬁes a landmark shift in
throughput, reproducibility, and robustness of these workﬂows.
While MS2-based quantiﬁcation of phosphopeptides via
isobaric tagging was found to have distorted accuracy, utilizing
an SPS-MS3 scan dramatically improved phosphopeptide
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quantitative accuracy. We demonstrated the technique via the
quantiﬁcation of tens of thousands of phosphopeptides from
ﬁve mouse livers and brains.
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Villeń, J.; Kubica, N.; Hoffman, G. R.; Cantley, L. C.; Gygi, S. P.;
Blenis, J. Science 2011, 332, 1322−1326.
(20) Wu, R.; Haas, W.; Dephoure, N.; Huttlin, E. L.; Zhai, B.; Sowa,
M. E.; Gygi, S. P. Nat. Methods 2011, 8, 677−683.
(21) Robitaille, A. M.; Christen, S.; Shimobayashi, M.; Cornu, M.;
Fava, L. L.; Moes, S.; Prescianotto-Baschong, C.; Sauer, U.; Jenoe, P.;
Hall, M. N. Science 2013, 339, 1320−1323.
(22) Zheng, Y.; Zhang, C.; Croucher, D. R.; Soliman, M. A.; St-
Denis, N.; Pasculescu, A.; Taylor, L.; Tate, S. A.; Hardy, W. R.; Colwill,
K.; Dai, A. Y.; Bagshaw, R.; Dennis, J. W.; Gingras, A.-C.; Daly, R. J.;
Pawson, T. Nature 2013, 499, 166−171.
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